The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 14, 2020

Filed:

Dec. 04, 2017
Applicant:

Expression Pathology, Inc., Rockville, MD (US);

Inventors:

Todd Hembrough, Gaithersburg, MD (US);

Fabiola Cecchi, Washington, DC (US);

Jean-Charles Soria, Villejuif, FR;

Assignee:

Expression Pathology, Inc., Rockville, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 33/24 (2019.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); A61K 31/519 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 33/24 (2013.01); A61K 31/519 (2013.01); A61P 35/00 (2018.01); G01N 33/57423 (2013.01); G01N 33/6848 (2013.01); G01N 2333/47 (2013.01); G01N 2333/4704 (2013.01); G01N 2333/705 (2013.01); G01N 2333/91017 (2013.01); G01N 2800/52 (2013.01); G01N 2800/60 (2013.01);
Abstract

Methods are provided for identifying whether a lung tumor will be responsive to treatment with the combination of the therapeutic agents cisplatin and pemetrexed. Specified ERCC1, TS, p16, and FRα fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in lung tumor cells collected from lung tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with the combination of cisplatin and pemetrexed therapeutic agents.


Find Patent Forward Citations

Loading…